SecBot SecBot
8-K ·Filed Jul 30, 2026

BAX

BAXTER INTERNATIONAL INC
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001628280-26-050795
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The significant EPS and revenue beat combined with raised guidance is a strong positive catalyst. Monitor the Q3 earnings call for sustainability of organic growth momentum and whether the tariff refund is a one-time benefit or signals broader trade policy tailwinds. The Novum IQ LVP shipment hold remains a headwind for Infusion Systems, but broad-based segment growth suggests underlying demand is solid.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$26.75
T+0 close · Jul 30, 2026 · via day close
Latest settled
−5.42%
T+60 · $25.30
Vs SPY
−7.89%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $26.75entry
  2. T+1 · 4mo ago −2.21%α −2.91% · $26.16
  3. T+5 · 3mo ago +0.97%α −2.65% · $27.01
  4. T+20 · 3mo ago −3.07%α −7.03% · $25.93
  5. T+60 · 25d ago −5.42%α −7.89% · $25.30
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Baxter reported Q2 2026 results that significantly exceeded consensus expectations, with adjusted EPS of $0.56 (vs $0.37 consensus, +51.4% beat) and revenue of $2.96B (vs $2.80B consensus, +5.7% beat). The company raised its full-year 2026 guidance: reported sales growth now 3-4% (from flat to 1%), organic sales growth 2-3% (from approximately flat), and adjusted EPS $1.95-$2.15 (from $1.85-$2.05). The beat was partly driven by a $0.11/share IEEPA tariff refund not previously contemplated in guidance.

Key Financial Metrics

EPS
$0.56
est $0.37 · +51.4%
Revenue
$3.0B
est $2.8B · +5.7% · +5.0% YoY
Rating
strong beat
Guidance
3% to 4% reported sales growth; 2% to 3% organic sales growth
raised
Free Cash Flow
$181.0M
Gross Margin
34.9%

Key Facts

  • Q2 2026 adjusted EPS $0.56 vs consensus $0.37 (+51.4% beat)
  • Q2 2026 revenue $2.96B vs consensus $2.80B (+5.7% beat)
  • Revenue grew 5% YoY on both reported and organic basis, with all segments and divisions growing
  • Full-year 2026 guidance raised: reported sales growth 3-4% (from flat to 1%), organic sales growth 2-3% (from approximately flat), adjusted EPS $1.95-$2.15 (from $1.85-$2.05)
  • GAAP EPS $0.26 vs $0.24 YoY (+8%); adjusted EPS $0.56 vs $0.59 YoY (-5%) due to higher-cost inventory and cost reclassification, partially offset by $0.11/share tariff refund
  • Free cash flow $181M in Q2, $257M YTD
  • Quarterly dividend declared at $0.01/share, payable October 1, 2026

Financial Impact

EPS beat of $0.19 (51.4%) on $0.37 consensus; revenue beat of $160M (5.7%) on $2.80B consensus; guidance raised by $0.10-$0.10 at midpoint for adjusted EPS and 2-3pp for sales growth

revenueepsguidancefree cash flow

Risk Factors

  • The $0.11/share tariff refund is non-recurring and may not repeat in H2 2026
  • Novum IQ LVP shipment and installation hold continues to pressure Infusion Systems sales
  • Adjusted EPS still declined 5% YoY due to higher-cost inventory and cost reclassification headwinds
  • Dividend remains at $0.01/share, signaling continued balance sheet constraints

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
8% bullish (24 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-050795
Document: bax-20260729.htm0001628280-26-050795
Document: 0001628280-26-050795-index-headers.html0001628280-26-050795
Document: 0001628280-26-050795-index.html0001628280-26-050795
Document: 0001628280-26-050795.txt0001628280-26-050795
8-K Data (Synthetic)0001628280-26-050795

Track record

15 reports on BAX

Performance horizon

2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +9.15% at T+5 after the Oct 29, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Oct 29, 202618d ago 8-K Bullish 6/10 Entry $23.50 to $25.65 Now $25.54 +8.68% ▲ +9.15% +13.87% vs SPY
  2. Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $24.92 to $25.49 Now $25.54 +2.49% ▲ +2.29% +4.28% vs SPY
  3. Oct 23, 202624d ago Institutional Cluster Neutral 2/10 Entry $25.30 to $23.00 Now $25.54 +0.95% ▼ −9.09% −8.53% vs SPY
  4. Aug 19, 202612w ago 8-K Neutral 3/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
  5. Aug 18, 202612w ago 8-K Mixed 5/10 Entry $26.64 to $26.50 Now $25.54 −4.13% ▼ −0.53% −0.14% vs SPY
  6. Aug 12, 202613w ago Institutional Cluster Bullish 4/10 Entry $26.95 to $26.64 Now $25.54 −5.23% ▼ −1.15% −0.71% vs SPY
  7. Aug 4, 202614w ago 8-K Neutral 4/10 Entry $28.35 to $27.61 Now $25.54 −9.91% ▼ −2.61% −2.51% vs SPY
  8. Jul 30, 202615w ago 8-K Bullish 7/10 Viewing Entry $26.75 to $27.01 Now $25.54 −4.52% ▲ +0.97% −2.65% vs SPY
  9. Jun 11, 202622w ago Institutional Cluster Bearish 6/10 Entry $20.49 to $19.39 Now $25.54 −24.65% ▲ +5.37% +5.80% vs SPY
  10. May 8, 202627w ago 8-K Neutral 2/10 Entry $17.53 to $17.79 Now $25.54 +45.69% ▲ +1.48% +1.57% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens Wed (10h 22m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026